Shares of Senseonics Holdings (NYSE: SENS) surged over 6% in pre-market trading on Monday after the company announced that its next-generation Eversense 365 continuous glucose monitoring (CGM) system has received clearance from the U.S. Food and Drug Administration (FDA).
The Eversense 365 is being hailed as a breakthrough in diabetes technology, as it is the world's first CGM system to offer a sensor that can last for one full year - a significant improvement over currently available short-term CGM sensors that need to be replaced every 10-14 days.
With a single sensor insertion, the Eversense 365 system provides people with diabetes an uninterrupted year of glucose monitoring, reducing the burden and inconvenience of frequent sensor changes. Additionally, the system offers seamless device connectivity, high accuracy, and improved discretion with on-body vibration alerts.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。